Korean biomaterials company making human/animal tissue-derived implants for dental, orthopedic and skin-regeneration procedures.
Korean biomaterials company making human/animal tissue-derived implants for dental, orthopedic and skin-regeneration procedures.
Sells processed tissue products from human donors, such as acellular dermal matrix, a graft used in reconstructive and aesthetic surgery, as well as bone and dental grafts, mainly through distributors in Korea and abroad. Each product needs separate regulatory approval, so launches follow approvals market by market.
Moat: narrow (regulatory licence, process know-how). Tissue-processing and regulatory approvals for implantable biomaterials are hard to replicate quickly.
Headquarters: Seoul, South Korea · Employees: 155
Size L&C BIO (290650.KS) is a South Korea Health Care company (Medical Specialties) with a market value of $943M, the 245th largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩20,100 on 18 Nov 2026.
Performance Over six months the shares fell 36.9%, against -12.1% for the median peer and -37.2% for the South Korea market (cap-weighted) — 2nd lowest of 21 in its peer set.
Growth Revenue grew 65.3% over the last twelve months (peer median +6.1%); the operating margin is 20.0% (peer median 8.9%).
Valuation It trades at 9.7× enterprise value to sales against a peer median of 3.1× (4th most expensive of 21).
Price implies For today's price to make sense, revenue must grow about 33% a year for seven years (Req g). Recent delivered growth is +21%, so the hurdle is +12 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 3.5 points below its cost of capital (8.7% WACC).
Next results Next results expected around 22 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩132B | ₩85.5B | ₩72.0B | ₩65.9B | ₩52.6B |
| Revenue growth | — | +19% | +9% | +25% | — |
| Gross profit | ₩74.8B | ₩41.3B | ₩33.4B | ₩31.8B | ₩25.6B |
| EBITDA | ₩38.9B | ₩11.6B | ₩10.1B | ₩12.7B | ₩13.7B |
| Net income | -₩93.2B | -₩138B | ₩142B | ₩48.4B | ₩4.54B |
| Free cash flow | ₩2.34B | -₩3.25B | -₩13.3B | -₩36.6B | -₩43.6B |
| Capital expenditure | ₩36.1B | ₩17.0B | ₩5.35B | ₩25.0B | ₩37.7B |
| Total debt | ₩62.4B | ₩92.2B | ₩124B | ₩82.1B | ₩81.9B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 290650.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -36.5% | -6.1% | lowest of 21 |
| 6-month return | -36.9% | -12.1% | 2nd lowest of 21 |
| Distance from 52-week high | -66.8% | -32.1% | 2nd lowest of 21 |
| Revenue growth (TTM) | +65.3% | +6.1% | highest of 21 |
| Operating margin | 20.0% | 8.9% | 4th highest of 21 |
| EV / Sales | 9.7× | 3.1× | 4th most expensive of 21 |
| Growth the price implies (Req g, 7 yrs) | 32.6% | 5.9% | 2nd most demanding of 13 |
| Growth delivered (Del g) | +21.0% | +11.9% | 2nd highest of 13 |
| Hurdle (Req g minus delivered) | +11.6 pp | -4.5 pp | 2nd most demanding of 13 |
| ROIC minus cost of capital | -3.5 pp | +2.8 pp | 7th lowest of 20 |
| EV / EBITDA | 32.8× | 9.5× | 2nd most expensive of 10 |
| Net debt / EBITDA | 0.3× | 0.3× | 5th least indebted of 10 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| L&C BIO 290650.KS | South Korea | $943M | -37% | +65% | 20% | 9.7× | 32.6% | +21.0% |
| Menicon 7780.T | Japan | $944M | +26% | +6% | 9% | 1.5× | n/a | n/a |
| Safilo SFL.MI | Italy | $953M | +42% | -4% | 9% | 0.9× | 1.3% | +4.7% |
| JINS 3046.T | Japan | $963M | -8% | +14% | 10% | 1.3× | -6.1% | +11.7% |
| Mani 7730.T | Japan | $965M | -7% | +10% | 30% | 3.9× | 3.3% | +13.9% |
| Kuros Biosciences KURN.SW | Switzerland | $907M | -12% | +41% | 6% | 5.5× | n/a | n/a |
| Artivion AORT | United States | $905M | -18% | +14% | 5% | 2.6× | n/a | n/a |
| INKON Life Technology 300143.SZ | China | $985M | -23% | +22% | 12% | 3.1× | 10.7% | +12.9% |
| Bioventus BVS | United States | $895M | -3% | +4% | 10% | 2.0× | 7.5% | +12.1% |
| Ceribell CBLL | United States | $995M | +42% | +31% | -70% | 8.3× | n/a | n/a |
| Aidite (Qinhuangdao) Technology 301580.SZ | China | $888M | -12% | +17% | 18% | 4.0× | 19.3% | +23.3% |
| Edan Instruments 300206.SZ | China | $1.00B | -19% | +14% | 17% | 2.5× | 6.9% | -2.9% |
| Shenzhen YHLO Biotech 688575.SS | China | $882M | -16% | +3% | 12% | 3.1× | 2.0% | +12.7% |
| Amoy Diagnostics 300685.SZ | China | $1.01B | -15% | +7% | 34% | 4.7× | 4.9% | +10.4% |
| Hangzhou Biotest Biotech 688767.SS | China | $878M | -12% | -4% | 3% | 10.4× | n/a | n/a |
| Xiangyu Medical 688626.SS | China | $877M | -38% | 0% | 4% | 7.2× | n/a | n/a |
| Tinavi Medical Technologies 688277.SS | China | $872M | -36% | -2% | -59% | 21.7× | n/a | n/a |
| PHC 6523.T | Japan | $1.02B | +34% | +3% | 8% | 0.9× | -4.0% | +3.5% |
| Inno Laser Technology 301021.SZ | China | $1.03B | -33% | +17% | 9% | 11.1× | 50.8% | +8.6% |
| Beijing Wandong Medical Technology 600055.SS | China | $1.03B | -26% | -11% | -33% | 3.0× | n/a | n/a |
| Eckert & Ziegler EUZ.DE | Germany | $1.03B | -2% | +4% | 26% | 2.7× | 7.7% | +12.1% |